Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 452Gastrointestinal 89Breast 85Gynecologic 77Genitourinary 73Head & Neck 62Dermatologic 43Sarcoma 30CNS 26Other solid neoplasm 25Lymphoid 23Other hematologic neoplasm 22Endocrine 13Plasma cell 12Other neoplasm 4Myeloid 4Classical hematology 3Other 2NET 1

Conditions

Anemia, Refractory, with Excess of Blasts 168Myelodysplastic Syndromes 160Leukemia 156Anemia 151Leukemia, Myeloid, Acute 144Neoplasms 124Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Leukemia, Myelomonocytic, Chronic 111Multiple Myeloma 90Myeloproliferative Disorders 89Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 76Hodgkin Disease 71Lymphoma 66Congenital Abnormalities 64Anemia, Refractory 64Venous Thromboembolism 63Thrombocytopenia 59Blast Crisis 57Leukemia, Myeloid, Chronic-Phase 56Leukemia, Myeloid, Accelerated Phase 52Lymphoma, Follicular 51Myelodysplastic-Myeloproliferative Diseases 48Anemia, Aplastic 46Primary Myelofibrosis 44Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 41Burkitt Lymphoma 41

Interventions

talazoparib 1SRA737 1Gemcitabine 1Epoetin Alfa 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × Classical hematology × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
201 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡